RESUMO
Objective:To explore the occurrence and risk factors of interstitial pneumonia (IP) in patients with diffuse large B-cell lymphoma (DLBCL) after the treatment of CHOP-like regimens containing liposomal doxorubicin.Methods:The clinical data of 145 newly diagnosed and newly treated DLBCL patients who were admitted to the Affiliated Tumor Hospital of Xinjiang Medical University from January 2013 to June 2020 were retrospectively analyzed, of which 73 cases were treated with RCDOP regimen containing liposomal doxorubicin, and 72 cases were treated with RCHOP regimen. The incidence of IP was compared between the two groups, and the risk factors of IP were analyzed by multivariate logistic regression.Results:In 145 patients, 34 patients (23.4%) developed IP; most cases of IP occurred during 3 to 5 cycles of chemotherapy, accounting for 79.4% (27/34); when IP occurred, the median cycles of chemotherapy was 4 cycles. The incidence of IP in RCDOP regimen group and RCHOP regimen group were 31.5% (23/73) and 15.3% (11/72), and the difference was statistically significant ( χ2 = 5.319, P < 0.05). Multivariate logistic regression analysis showed that the application of liposomal doxorubicin ( OR = 2.416, 95% CI 1.059-5.509, P = 0.036) and age ≥60 years old ( OR = 2.505, 95% CI 1.127-5.567, P = 0.024) were independent risk factors for the occurrence of IP. Conclusions:The application of liposomal doxorubicin is a risk factor for the occurrence of IP in DLBCL patients. The prevention and monitoring of IP should be strengthened after 4 cycles of treatment with RCDOP regimen, especially for patient ≥ 60 years of age.
RESUMO
Objective:To investigate the clinical significance of Bcl-6, c-myc gene abnormalities in Xinjiang Uygur and Han dif-fused large B-cell lymphoma (DLBCL) subtypes. Methods:Bcl-6, c-myc gene was detected by fluorescence in situ hybridization in 233 patients with DLBCL . A relationship was observed among Bcl-6, c-myc gene translocation, and clinical data in DLBCL patients. In addition, a difference was observed among Bcl-6, c-myc gene translocation, and different ethnic groups in different subtypes of DLB-CL. Results:Among the 233 patients, 51 cases (21.89%) had rearranged Bcl 6 gene, and 39 cases (16.74%) had rearranged c-myc gene. Bcl-6 gene translocation and expression was related with age, gender, disease location, clinical stage, and LDH levels (P>0.05), but was not related with nationality , international prognostic index score, extranodal involvement, B symptoms, DLBCL subtypes, and recent efficacy (P0.05), but was not related with nationality, IPI score, extranodal involvement, B symptoms, and recent effica-cy (P0.05). By con-trast, in the Uygur and Han non-GCB groups, Bcl-6, c-myc gene translocation showed significant difference (P>0.05). Conclusion:Bcl-6, C-myc gene translocation was related with age, gender, disease location, clinical stage, and LDH levels. Bcl-6 gene translocation was also correlated with different subtypes of DLBCL.
RESUMO
Objective To observe and compare efficacy and safety of vinorelbine (NVB) plus ifosfamide (IFO) (NI regimen) and NVB plus cisplatin(DDP) (NP regimen) in treatment of metastatic breast cancer.Methods 82 cases of recurrent and metastatic breast cancer after the failure of treatment with anthracyclines and taxanes,40 cases were treated with NI regimen (NVB 25 mg/m2,day 1,day 8,IFO 1.2 g/m2,day 1,day 2,day 3),and the other 42 cases received NP regimen (NVB 25 mg/m2,day 1,day 8,DDP 25 mg/m2,day 1,day 2,day 3).Both groups were constituted of 21 days one cycle.After 2 cycles of chemotherapy,the response rate and side effects were evaluated.Results All 82 cases were evaluated for objective response.The total response rate of NI group and NP group were 52.50 ％ (21/40) and 57.14 ％ (24/42).There was no significiant difference (P ＞ 0.05).By analysis of the correlative factors,the total response rate in treatment of triple-negative breast cancer of NI group was 43.75 ％ (7/16),and that of NP group was 44.44 ％ (8/18).The two rates were also approximative (P ＞ 0.05).Main side effects were both bonemarrow suppression and gastrointestinal reaction.Bonemarrow suppression rate at grade Ⅲ-Ⅳ of NI group [57.5 ％ (23/40)] had no significant difference compared with that of NP group[57.14 ％ (24/42)] (P ＞ 0.05).But grade Ⅲ-Ⅳ gastrointestinal rate of NI group [7.50 ％ (3/40)] was significantly lower than that of NP group [26.19％(11/42)](P ＜ 0.05).Conclusion NI regimen in treatment of advanced breast cancer is effective,and it shows a similar response rate compared with NP regimen.Also it is effective for triple negeative breast cancers.The toxicity can be tolerated,and the gastrointestinal reaction rate of NI regimen is lower.NI regimen is a good choose in treatment of advanced breast cancer.
RESUMO
0.05).The expression of survivin mRNA and BCRP mRNA was correlated with therapeutic effect of chemotherapy(P